G R E AT E R H A R T F O R D ' S B U S I N E S S N E W S w w w. H a r t f o rd B u s i n e s s . c o m
For more B2B news visit
AUGUST 15, 2016
Volume 24, Number 37
$3.00
Subscribe
online
JOIN US!
'BLACK TIE &
BLUE JEANS'
ANNIVERSARY EVENT
WEDNESDAY, SEPT. 14, 2016
CT CONVENTION CENTER | HARTFORD
20th
ANNIVERSARY
19
9
7-2
0
1
6
Index
■ Reporter's Notebook: PG. 5
■ Week in Review: PG. 6
■ The List: PG. 10
■ Deal Watch: PG. 11
■ Town Profile: PG. 16
■ Movers & Shakers: PG. 18
■ Opinion & Commentary: PG. 20
FOCUS: HEALTH CARE
Wary Docs
A new law passed by Congress last year is
changing the way doctors will be paid for treating
Medicare patients, and not all Connecticut
physicians are on board with the shift. PG. 8
Manufacturer Spotlight
Precision Punch is among some 3,000 U.S.
producers engaged in metal-stamping and
fabrication, a manufacturing segment that
generates an estimated $130 billion a year in
sales. Find out how the Berlin company
differentiates itself from the competition. PG. 3
UConn's startup
interns build CT's
STEM-talent pipeline
By Matt Pilon
mpilon@HartfordBusiness.com
E
arlier this month, scientists,
engineers and entrepreneurs
looked on as UConn under-
graduate and graduate-level stu-
dents presented what they accom-
plished as summer interns working
at the school's incubator companies
in Farmington and Storrs.
Hailing from more than a
dozen majors — and some already
with STEM-related work expe-
rience under their belts — the
students' projects were equally
diverse, ranging from the creation
of marketing plans for software
Building
Bioscience
A N H B J S E R I E S O N C T ' S B I O S C I E N C E S E C T O R
Research Pivot
Scientist Guangwei Yang at work
at Achillion Pharmaceuticals' New
Haven laboratory-headquarters.
P
H
O
T
O
|
C
O
N
T
R
I
B
U
T
E
D
H
artford Business Journal's series on
Connecticut's bioscience industry
continues this week with a look at New
Haven-based Achillion Pharmaceuticals.
Following its 2015 licensing agreement
with Johnson & Johnson Co.'s Janssen
Pharmaceuticals division for its Hepatitis C
treatments, Achillion is using its $426.5 mil-
lion cash horde to self-fund its latest pivot into
research and development, and perhaps even-
tual commercialization, of a new class of treat-
ments. Find out more on PG. 12
Scott Conroy, a graduate student
in applied genomics, interned for
Frequency Therapeutics, which is
developing a way to regrow inner
ear hairs used for hearing.
Continued on page 14
H
B
J
P
H
O
T
O
|
M
A
T
T
P
I
L
O
N
Achillion's deep
pockets will fuel
its next chapter
